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ABSTRACT
Background: The ability to distinguish which hrHPV infections predispose to 
significant disease is ever more pressing as a result of the increasing move to hrHPV 
testing for primary cervical screening. A risk-stratifier or “triage” of infection should 
ideally be objective and suitable for automation given the scale of screening. 
Results: CCL2, CCL3, CCL4, CXCL1, CXCL8 and CXCL12 emerged as the strongest, 
candidate biomarkers to detect underlying disease [cervical intraepithelial neoplasia grade 
2 or worse (CIN2+)]. For CIN2+, CCL2 had the highest area under the curve (AUC) of 0.722 
with a specificity of 82%. A combined biomarker panel of six chemokines CCL2, CCL3, 
CCL4, CXCL1, CXCL8, and CXCL12 provides a sensitivity of 71% and specificity of 67%.
Conclusion: The present work demonstrates that the levels of five chemokine-
proteins are indicative of underlying disease. We demonstrate technical feasibility 
and promising clinical performance of a chemokine-based biomarker panel, equivalent 
to that of other triage options. Further assessment in longitudinal series is now 
warranted.
Methods: A panel of 31 chemokines were investigated for expression in routinely 
taken archived and prospective cervical liquid based cytology (LBC) samples using 
Human Chemokine Proteomic Array kit. Nine chemokines were further validated using 
Procartaplex assay on the Luminex platform. 
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INTRODUCTION
Persistent infection with high-risk (oncogenic) 
Human Papilloma Virus (hrHPV) causes >95% of cervical 
cancers [1]. Cervical hrHPV infection is common but most 
infections clear naturally. In a small proportion of women, 
however, infection persists and persistent infection can 
lead to the development of cervical lesions referred to 
as cervical intraepithelial neoplasia (CIN grades 1 to 3 
according to increasing severity) [2, 3]. If left untreated 
a proportion of lesions will develop into cervical cancer. 
Around thirteen hrHPV types cause 99% of all cervical 
cancers. Two types, HPV16 and HPV18 cause over 70% 
of cancers [4]. 
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In women who fail to clear infection it is reasonable 
to hypothesise that the local immune response profile may 
differ from that in women who have cleared infection. 
In particular, innate immune response proteins such as 
chemokines, produced by cervical cells should be detectable 
in proteins extracted from cervical liquid based cytology 
(LBC) samples. Chemokines are produced in response 
to any hrHPV infection independent of underlying type 
(unlike antibodies or T cell responses) and are made in high 
amounts during persistent viral infection [5]. Their detection 
may therefore serve as a biomarker to distinguish clinically 
significant infection and associated disease. 
Cervical screening is changing globally from a 
cytology based approach to the molecular detection 
of hrHPV types [6–9]. While the sensitivity of hrHPV 
testing for CIN2+ has been demonstrated, the specificity 
of hrHPV testing to detect disease is sub-optimal. Several 
triage tests have been suggested to risk-stratify women 
who are hrHPV positive, including cytology and HPV 
16/18 genotyping (where women with 16/18 infection 
are sent to colposcopy and women with other high risk 
are managed conservatively) [10]. However,  there is 
international consensus that better triage tests are needed 
urgently to determine which hrHPV positive women are 
truly at risk of significant disease [11]. 
The aim of the present work was to determine 
whether chemokines are differentially expressed in women 
with and without cervical disease in order to determine 
the feasibility of this approach for the risk-stratification of 
hrHPV infection. 
RESULTS
Chemokines are differentially expressed in 
different grades of hrHPV induced CIN
A proteomic array including 31 chemokines was tested 
on pooled protein extracts from LBC samples associated with 
different CIN grades. (Figure 1). Out of 31 chemokines on 
the array, CCL2, CCL5, CCL28, CXCL5, CXCL9, CXCL10, 
CXCL11, CXCL12 and Chemerin were upregulated in the 
samples from women with CIN3 compared to samples 
associated with negative HPV and normal cytology status. 
A total of three chemokines (Midkine, CXCL4, CXCL7) 
were highly expressed in CIN1 but not in CIN2 or CIN3; and 
CXCL1 was highly expressed in CIN1 and CIN2 but not in 
CIN3. CXCL8 was highly expressed in all sample categories. 
Based on these results, a combination of chemokines was 
selected for further analysis.
Chemokine expression levels are indicative of 
disease severity 
To investigate quantitative expression of chemokines 
in LBC samples and to validate results from the proteomic 
array, a multiplex bead-based Procartaplex™ assay 
was performed. As indicated in the Methods section, 
the commercially available 8-plex Procartaplex assay 
used for validation included five chemokines of interest 
identified in the proteomic array - CCL2, CXCL1, 
CXCL8, CXCL10 and CXCL12 and also three others – 
CCL3, CCL4, CCL11. CCL11 and CXCL10 were below 
the threshold for measurement by the multiplex assay and 
CCL4 expression levels showed no significant difference 
between any disease categories (p = 0.37 for CIN2+ and 
p = 0.501 for CIN3+). However, CCL2, CCL3, CXCL1, 
CXCL8 and CXCL12 all showed significantly different 
expression with higher levels of expression generally 
observed in CIN2+ (p < 0.0001, Figure 2). When assessing 
CIN3+ as outcome (compared to ≤CIN2. Figure 3), CCL2, 
CCL3, CXCL1 and CXCL8 showed significantly higher 
expression (p < 0.0001) whereas CXCL12 (p = 0.061) 
did not.
Individual and combined clinical performance 
of chemokines for the detection of CIN2+ and 
CIN3+ 
Univariate analysis was performed for each 
chemokine individually to identify the sensitivity and 
specificity for the detection of CIN2+ and CIN3+ 
(Table 1A). Sensitivity, specificity and overall predictive 
ability of each chemokine varied dependent on the 
disease threshold considered. For CIN2+, CCL2 has the 
highest AUC of 0.722 with sensitivity and specificity 
of 55.6% and 82% respectively. CXCL1 provided the 
highest sensitivity (73.4%) and CCL2 offered the highest 
specificity (82%). For CIN3+ as the disease threshold, 
CCL2 had the highest AUC of 0.648 with sensitivity and 
specificity of 59.5% and 64% respectively. CXCL8 had 
the highest sensitivity (60.8%) and CCL3 had the highest 
specificity (70.8%). 
A multivariate model using a logistic regression 
framework was designed to identify potential chemokine 
biomarker combinations which were predictive of disease. 
Of the interactions considered, two significant interactions 
were found using the CIN2+ disease threshold; CXCL1* 
CXCL8 (p = 0.000135) and CCL3* CCL4 (p = 0.000119). 
No significant interactions were found for the CIN3+ 
thresholds but for purposes of comparability, these 
interactions were also considered for the CIN3+ outcome 
(Table 1B). Using a model of all 6 chemokines plus 
interaction between CCL3 and CCL4 (model 4) provided 
the best predictability with a sensitivity and specificity of 
70.97% and 66.67% (for CIN2+) and 48.65% and 67.08% 
(for CIN3+) respectively. Models 6 and 7 have a high 
AUC (75% for CIN2+ and 67% for CIN3+). Using the two 
biomarkers CCL2 and CXCL1 provides high specificity of 
82% (for CIN2+) and 66% (for CIN3+) but with a lower 
sensitivity. 
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Figure 1: Proteomic array shows detection of chemokines in pooled aliquots from 9 samples in following categories hrHPV negative, 
cytological normal; hrHPV positive, CIN1; 3) hrHPV positive CIN2; and 4) hrHPV positive CIN3 (A). Relative pixel density ratio for each 
protein on the array was calculated using ImageJ by normalising to negative controls (NEG CONTROL) (B). Heatmap representing array 
results with pixel density. 
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Figure 2: Distribution of chemokine level (pg/200 ug) for ≤CIN1 versus CIN2+. Boxplots demonstrate the median, lower and 
upper quartile of the values, with the mean value represented as a triangle. Individual data points are shown as grey dots. Values deemed to 
be outliers of the distribution are shown as black dots. P values were calculated using Mann–Whitney test. 
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Figure 3: Distribution of chemokine level (pg/200 ug) for categorised disease groupings hrHPV positive ≤CIN2 versus 
CIN3+.  Boxplots demonstrate the median, lower and upper quartile of the values, with the mean value represented as a triangle. Individual 
data points are shown as grey dots. Values deemed to be outliers of the distribution are shown as black dots. P values were calculated using 
Mann–Whitney test. 
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Clinical performance of HPV16/18 genotyping 
for the detection of CIN2+ and CIN3+ 
For the 483 hrHPV positive women in our sample 
set, we had HPV16/18 limited genotyping information 
using the Abbott RealTime HPV test. According to this, 
155/239 CIN2+ and 99/ 138 CIN3+ had a 16/18 infection. 
Sensitivity and specificity of HPV16/18 genotyping was 
64.8% (95% CI: 58.4–70.8) and 43.4% (95% CI: 37.1–
49.9%) for CIN2+ and 71.7% (95% CI: 63.6–78.9) and 
43.4% (95% CI: 38.4–49.1%) respectively for CIN3+. 
DISCUSSION 
Currently the most evidenced triage options for 
hrHPV positive women detected at screening are cytology 
Table 1A: Univariate analysis summarising the individual ability of each chemokine to predict the disease state based 
on two disease cut-offs –CIN2+ and CIN 3+
CIN2+* CIN3+**
Chemokine AUC Accuracy Sensitivity Specificity AUC Accuracy Sensitivity Specificity
CCL2 0.722 68.1% 55.6% 82.0% 0.648 62.55% 59.46% 63.98%
CCL3 0.699 66.8% 56.5% 78.4% 0.647 66.38% 56.76% 70.81%
CCL4 0.469 47.7% 38.7% 57.7% 0.528 63.83% 32.43% 78.26%
CXCL1 0.706 67.2% 73.4% 60.4% 0.645 65.96% 59.46% 68.94%
CXCL8 0.660 63.8% 52.4% 76.6% 0.595 57.02% 60.81% 55.28%
CXCL12 0.646 62.6% 58.1% 67.6% 0.566 48.09% 81.08% 32.92%
*Proportion of CIN2+ in test data set, 53%. **Proportion of CIN3+ in test data set 31.5%. 
Table 1B: Summary of model predictability where combinations of chemokines are considered in a logistic regression 
framework
CIN2+* CIN3+**
Model AUC Accuracy Sensitivity Specificity AUC Accuracy Sensitivity Specificity
Model 1: All 6 chemokines 0.704 66.81% 67.74% 65.77% 0.580 62.13% 48.65% 68.32%
Model 2: All 6 chemokines 
plus interactions 
CXCL8*CXCL1  and 
CCL3*CCL4 0.726 68.51% 59.68% 78.38% 0.494 31.91% 83.78% 8.07%
Model 3: All 6 chemokines 
plus interaction 
CXCL8*CXCL1 0.711 66.38% 54.84% 79.28% 0.522 63.40% 35.14% 76.40%
Model 4: All 6 chemokines 
plus interaction 
CCL3*CCL4 0.723 68.94% 70.97% 66.67% 0.546 61.28% 48.65% 67.08%
Model 5: CXCL8 and CCL2 0.696 65.96% 58.87% 73.87% 0.601 58.72% 62.16% 57.14%
Model 6: CXCL1 and CCL2 0.752 69.36% 57.26% 82.88% 0.667 65.53% 63.51% 66.46%
Model 7: CXCL1 and 
CCL2 and interaction 
CXCL1*CCL2 0.752 69.79% 58.06% 82.88% 0.669 65.11% 66.22% 64.60%
Model 8: CXCL1 and 
CXCL8 0.687 64.68% 49.19% 81.98% 0.618 57.45% 72.97% 50.31%
Model 9: CXCL1 and 
CXCL8 and interaction 
CXCL1*CXCL8 0.703 65.53% 49.19% 83.78% 0.561 58.72% 50.00% 62.73%
Model 10: CXCL1, CXCL8 
and CCL2 0.709 66.38% 52.42% 81.98% 0.619 58.30% 72.97% 51.55%
*Proportion of CIN2+ in test data set, 53%. **Proportion of CIN3+ in test data set 31.5%.
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with or without adjunctive p16/Ki67 staining, HPV16/18 
genotyping and viral and host DNA methylation 
markers [12]. However, none of the above satisfy all the 
requirements of an ideal triage test: - 1) high specificity 
for CIN2+; 2) objectivity; 3) high-throughput suitable for 
automation; 4) amenable to a wide range of biospecimen 
types and 5) produced independently of the infecting virus 
type. Therefore, there is urgent need for new biomarkers to 
risk-stratify hrHPV positive women. 
The immune response plays a central role in 
clearing transient HPV infections. Persistent infection 
and progression to cervical cancer occurs in only a 
minority of hrHPV positive women. Elevated levels of 
pro-inflammatory chemokines are indicative of persistent 
HPV infection and associated carcinogenesis [13]. Several 
of these pro-inflammatory chemokines such as CXCL1, 
CXCL8 and CXCL12 drive cancer progression by 
facilitating cell growth, survival and migration and inducing 
angiogenesis [14–17]. Other chemokines such as CCL2, 
CCL3, CCL4 promote tumour invasion and metastases 
[18–23].
Our results show that chemokine signature differs 
with severity of disease. Certain chemokines CCL2, 
CCL5, CCL28, CXCL5, CXCL9, CXCL10, CXCL11, 
CXCL12 and Chemerin were upregulated in the samples 
from women with CIN3 vs no disease. On the other hand, 
chemokines Midkine, CXCL4, CXCL7 were highly 
expressed in CIN1 but not in CIN2 or CIN3 and CXCL1 
was highly expressed in CIN1 and CIN2 but not in CIN3. 
CXCL8 expression also increased with severity of disease. 
Validation of these findings was performed on a multiplex 
Bioplex assay which showed that CCL2, CCL3, CXCL1, 
CXCL8 and CXCL12 were upregulated in hrHPV 
positive women with CIN2+ compared to hrHPV positive 
women with negative cytology or CIN1 histology. Our 
study backs previous findings by Cicchini et al [24] who 
showed, using gene expression data from human cervical 
tissue specimens, that CCL3, CCL19, CXCL8, CXCL9 
and CXCL11 mRNA levels increased progressively with 
disease severity while CCL20, CXCL1, CXCL2, CXCL5, 
and CXCL6 were upregulated in early transition from 
normal to CIN1/2 and CCL8 and CXCL12 increased in 
transition to invasive tumours. Further, expression of 
CXCL1, CXCL2, CXCL8, CXCL10, and CXCL11 was 
significantly increased in W12G and W12GPXY cells 
compared to NIKS [24]. While both W12 and NIKS cells 
are transformed human keratinocyte cell lines, W12 cell 
lines have HPV-16 while NIKS do not. This indicates a 
role of HPV in the overexpression of these chemokines. 
Other small scale studies by Zanotta et al shows that 
CCL7, CXCL9, CXCL12 were overexpressed in women 
with cytological abnormalities [23] and Iwata et al shows 
that CXCL8 was upregulated in High grade squamous 
intraepithelial neoplasia (HSIL) compared to  Low grade 
squamous intraepithelial neoplasia (LSIL) [25].
In the era of HPV primary screening, there is a need 
for robust triage systems which have a high specificity for 
disease. Our univariate analysis indicates that CCL2 and 
CXCL8 can act as individual biomarkers with a specificity 
for detection of CIN2+ of over 75%. Multivariate analysis 
using combined biomarkers show that Model 4 measuring 
all 6 chemokines plus an interaction term between CCL3 and 
CCL4 gives a sensitivity of 70.97% and specificity of 66.67% 
for detection of CIN2+. Within our sample set, we compared 
performance of the chemokine panel with HPV16/18 limited 
genotyping as a triage strategy. For CIN2+, the sensitivity of 
the combined chemokine marker set (70.97%) is higher than 
the sensitivity of HPV16/18 limited genotyping (64.8%) as 
is its specificity (66.67% v 43.4%). Similar results were seen 
for a CIN3+ disease threshold.  
A strength of our study is its relatively large sample 
size and level of disease annotation, compared to other 
feasibility studies that have measured immune biomarkers 
of cervical disease [23–30]. Our study also made use of 
samples of the type routinely used for cervical screening 
programme in the UK and beyond. One of the challenges 
of using a quantitative protein-based assay is that a method 
of standardisation/normalisation is required to account for 
inter-sample variability. For this purpose, we standardised 
the amount of protein input per sample. Further, we 
incorporated a technical validation control through the 
assessment of CXCL8. 
However, the present work has certain limitations 
which we aim to address in the future. The sample 
incorporated archived samples, some of which had been 
stored for over 5 years. This may have contributed to the 
10% invalidity rate which in a routine setting would be 
unacceptable. Additionally, the sample set was enriched for 
disease given the incorporation of a colposcopy population 
and was not, therefore, representative of a primary 
screening context. This said, feasibility assessment of 
candidate biomarkers in a high-prevalence disease setting 
has precedent and is consistent with overarching cancer 
biomarker development road-maps [31] and also road-maps 
specific to the evaluation of new biomarkers for cervical 
screening [32]. 
The data presented demonstrate that certain 
chemokine proteins are associated with high grade disease 
and can be measured in routinely taken cervical clinical 
samples. Further, the pattern of chemokine association 
reconciles with data from mechanistic studies that have 
shown a functional role of these proteins in tumorigenic 
processes. While the chemokine biomarker panel shows 
promise in its performance for detection of CIN2+ and 
CIN3+, there is scope for improvement. Future work is 
focussed on further optimisation of the assay to improve 
the clinical performance. This will involve looking at 
alternate antibodies and platforms for detection and 
improving technical sensitivity of the assay. Another stream 
of work is ongoing investigation of expression levels of the 
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chemokines at the mRNA level to assess their suitability as 
a triage test. Our results here show that further investigation 
of the biomarkers is certainly warranted, including in a 
primary screening prospective setting to further validate 
this novel and objective approach to the risk-stratification 
of HPV infection.
MATERIALS AND METHODS
Sample collection 
The study involved an initial screening (pilot study) 
of chemokines using Human Chemokine proteomic array on 
a small panel of LBC samples (N = 36). Following on from 
this, a validation study was carried out using ProcartaPlex 
multiplex assay on a larger panel of samples (N = 1051). 
The target sample size for the validation study 
was calculated a priori to be 1050 samples, of which at 
least ~30% would be CIN2+ and ~30% normal or CIN1 
(on follow-up histological assessment). The sample set 
was designed to incorporate samples from a prospective 
colposcopy cohort, where colposcopy had been indicated 
due to preceding abnormal cytology (N = 500) in addition 
to samples from the Scottish HPV Archive (N = 550). 
This sample size gave the ability to estimate with 95% 
confidence a test with sensitivity of 0.85 and specificity 
of 0.75 to within ±5%. The final analysis was comprised 
of 378 samples from the colposcopy cohort and larger 
number of archived samples (N = 673) to achieve the 
desired sample size. 
All cervical samples were collected into ThinPrep-
Preservcyt™ liquid based cytology transport medium 
(Hologic, Crawley, UK). Samples collected at the colposcopy 
clinic were aliquoted within 24 hours of collection and 
stored at –80° C. Archived samples were obtained as 1.5 ml 
aliquots that had been stored at –80° C for 3–5 years and 
underlying cytopathology and histopathology information 
(where indicated) was obtained. Cytology classification 
was according to British Association for Cytopathology 
criteria. Cytology results were classed as negative (for any 
abnormality), low grade (borderline squamous changes, 
koilocytosis, and low grade dyskaryosis) and high grade 
(which includes moderate dyskaryosis and worse) [2]. 
Histology results (both for prospective and archived samples) 
were obtained and classified as -No biopsy taken, Normal 
biopsy, CIN1, CIN2, CIN3. No histology result was obtained 
for women with negative cytological assessment. 
Governance
Anonymised archived liquid based cytology 
(LBC) cervical smear samples were obtained from the 
Scottish National HPV Archive (http://www.shine.mvm.
ed.ac.uk/archive.shtml), which holds Research Ethics 
Committee approval for Research Tissue banks (REC 
Ref 11/AL/0174) for provision of samples for HPV 
related research after approval from the Archive Steering 
Committee. Samples were made available for this study 
through approval (HPV Archive Application #0014). 
Favourable ethical opinion for the prospective colposcopy 
sample collection was also obtained (REF 12/SS/0034). 
HPV testing
All samples were analysed for hrHPV infection using 
the RealTime High Risk HPV Assay (Abbott Molecular, 
US) following the manufacturer’s instructions. This 
assay is considered clinically validated for use in primary 
cervical screening [33], detects 14 high risk types and offers 
separate, concurrent genotyping of HPV types 16 and 18. 
Extraction of protein from LBC Samples 
Protein was extracted from all 1051 LBC samples 
using the chloroform methanol extraction method 
published previously [34]. Protein concentration was 
determined by Pierce BCA assay (Thermo Scientific, UK). 
Human chemokine proteomic array
Antibody-based Human Chemokine Proteomic 
Array kit (Cat. No. ARY017, R & D systems, USA) was 
used to test expression of chemokines in LBC samples. 
Samples were categorised into the following groups 1) 
hrHPV negative, cytology negative; 2) hrHPV positive, 
CIN1; 3) hrHPV positive CIN2 and 4) hrHPV positive 
CIN3. Protein extracts from nine archived samples (10 µg 
each) associated with each category were pooled and 
tested. The assay was performed as previously described 
[34] and pixel density of individual spots was analysed on 
inverted images with Image-J software. A heatmap was 
generated using GraphPad Prism 7. 
Procarta multiplex assay 
Protein extracted as above from individual samples 
was tested for presence of CCL2, CCL3, CCL4, CCL5, 
CCL11, CXCL1, CXCL8, CXCL10 and CXCL12 by 
ProcartaPlex assay (Affymetrix eBioscience, Hatfield, 
UK). The assay was performed using 10µg protein per 
sample according to manufacturer’s guidelines and 
detected on a Bio-Rad Bio-Plex 200 HTF multiplex assay 
system. A sample was considered valid for analysis is the 
CXCL8 value was higher than100 pg/200 µg protein.
Of the 1051 samples analysed using ProcartaPlex, 
exclusions were made due to three failed experimental 
runs (error in experimental standards), CXCL8 value 
(<100 pg/200 µg protein) or missing clinical data 
rendering an analysable sample set of 648. When stratified 
by HPV status (to include only hrHPV positive samples) 
our final sample set (N = 476) incorporated 181 samples 
with normal cytology/histology, 58 CIN1, 100 CIN2, 
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135 CIN3, 1 Cervical Glandular intraepithelial neoplasia 
(CGIN) and 1 early invasive squamous cancer (Table 2). 
Statistical analysis 
Procartaplex results were visualised by boxplots to 
compare the distribution of chemokine values for CIN2+ 
or CIN3+ and the Wilcoxon–Mann–Whitney test used 
to compare the distributions chemokine values at each 
disease threshold.
To assess the ability to detect disease, initially each 
chemokine alone (univariate analysis) was evaluated in 
its ability to make predictions for both disease thresholds 
using logistic regression. We then considered the 
possibility of significant interactions between chemokines 
and conducted tests of interaction between all pairs of 
chemokines. This resulted in 15 tests of interaction for 
each disease threshold. To account for the multiplicity of 
testing for each threshold, a Bonferonni correction was 
applied to the significance level used and interactions with 
p-values less than α = 0.05/15 = 0.003 were considered 
to be statistically significant and investigated further. All 
chemokines and significant interactions were included 
in a multivariable logistic regression model. Model 
reduction was performed using backwards selection to 
ascertain if a statistically optimal model could be found, 
with chemokines removed using the least significant 
chemokine first according to the likelihood ratio test. The 
model reduction stopped when all remaining chemokines 
were significant at the 5% level. In addition, models with 
a combination of chemokines deemed to be of clinical 
interest were also considered.  
A model build, with both univariate and multivariate 
estimation, was conducted using the training set, which 
was a randomly chosen sample of 50% of the data. The 
ability of the model to predict diseases status was then 
evaluated using the remaining 50% of the data. The overall 
predictability of the model was assessed using the area 
under the curve (AUC) and the sensitivity and specificity 
of the model was assessed using the probability of disease 
threshold which optimises the AUC. In the interests of 
comparability, the same statistical models were compared 
for both end points. All statistical analysis was performed 
using the Statistics package R version 3.2.3.
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